Publication

An instrument dedicated for modelling of pulmonary radiotherapy

Niezink, A. G. H., Dollekamp, N. J., Elzinga, H. J., Borger, D., Boer, E. J. H., Ubbels, J. F., Woltman- van Iersel, M., van der Leest, A. H. D., Beijert, M., Groen, H. J. M., Kraan, J., Hiltermann, T. J. N., Wekken, van der, A. J., van Putten, J. W. G., Rutgers, S. R., Pieterman, R. M., de Hosson, S. M., Roenhorst, A. W. J., Langendijk, J. A. & Widder, J., Apr-2015, In : Radiotherapy and Oncology. 115, 1, p. 3-8 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Niezink, A. G. H., Dollekamp, N. J., Elzinga, H. J., Borger, D., Boer, E. J. H., Ubbels, J. F., ... Widder, J. (2015). An instrument dedicated for modelling of pulmonary radiotherapy. Radiotherapy and Oncology, 115(1), 3-8. https://doi.org/10.1016/j.radonc.2015.03.020

Author

Niezink, Anne G. H. ; Dollekamp, Nienke J. ; Elzinga, Harriet J. ; Borger, Denise ; Boer, Eduard J. H. ; Ubbels, Jan F. ; Woltman- van Iersel, Marleen ; van der Leest, Annija H. D. ; Beijert, Max ; Groen, Harry J. M. ; Kraan, Jan ; Hiltermann, Thijo J. N. ; Wekken, van der, Anthonie J. ; van Putten, John W. G. ; Rutgers, Steven R. ; Pieterman, Remge M. ; de Hosson, Sander M. ; Roenhorst, Anke W. J. ; Langendijk, Johannes A. ; Widder, Joachim. / An instrument dedicated for modelling of pulmonary radiotherapy. In: Radiotherapy and Oncology. 2015 ; Vol. 115, No. 1. pp. 3-8.

Harvard

Niezink, AGH, Dollekamp, NJ, Elzinga, HJ, Borger, D, Boer, EJH, Ubbels, JF, Woltman- van Iersel, M, van der Leest, AHD, Beijert, M, Groen, HJM, Kraan, J, Hiltermann, TJN, Wekken, van der, AJ, van Putten, JWG, Rutgers, SR, Pieterman, RM, de Hosson, SM, Roenhorst, AWJ, Langendijk, JA & Widder, J 2015, 'An instrument dedicated for modelling of pulmonary radiotherapy', Radiotherapy and Oncology, vol. 115, no. 1, pp. 3-8. https://doi.org/10.1016/j.radonc.2015.03.020

Standard

An instrument dedicated for modelling of pulmonary radiotherapy. / Niezink, Anne G. H.; Dollekamp, Nienke J.; Elzinga, Harriet J.; Borger, Denise; Boer, Eduard J. H.; Ubbels, Jan F.; Woltman- van Iersel, Marleen; van der Leest, Annija H. D.; Beijert, Max; Groen, Harry J. M. ; Kraan, Jan; Hiltermann, Thijo J. N.; Wekken, van der, Anthonie J.; van Putten, John W. G.; Rutgers, Steven R.; Pieterman, Remge M.; de Hosson, Sander M.; Roenhorst, Anke W. J.; Langendijk, Johannes A.; Widder, Joachim.

In: Radiotherapy and Oncology, Vol. 115, No. 1, 04.2015, p. 3-8.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Niezink AGH, Dollekamp NJ, Elzinga HJ, Borger D, Boer EJH, Ubbels JF et al. An instrument dedicated for modelling of pulmonary radiotherapy. Radiotherapy and Oncology. 2015 Apr;115(1):3-8. https://doi.org/10.1016/j.radonc.2015.03.020


BibTeX

@article{39c3c8780223449396cf0de0dc0a73d8,
title = "An instrument dedicated for modelling of pulmonary radiotherapy",
abstract = "Background and purpose: Radiotherapy plays a pivotal role in lung cancer treatment. Selection of patients for new (radio)therapeutic options aiming at improving outcomes requires reliable and validated prediction models. We present the implementation of a prospective platform for evaluation and development of lung radiotherapy (proPED-LUNG) as an instrument enabling multidimensional predictive modelling.Materials and methods: ProPED-LUNG was designed to comprise relevant baseline and follow up data of patients receiving pulmonary radiotherapy with curative intent. Patient characteristics, diagnostic and staging information, treatment parameters including full dose-volume-histograms, tumour control, survival, and toxicity are scored. Besides physician-rated data, a range of patient-rated data regarding symptoms and health-related quality-of-life are collected.Results: After 18 months of accrual, 315 patients have been included (accrual rate, 18 per month). Of the first hundred patients included, 70 received conformal (chemo)radiotherapy and 30 underwent stereotactic radiotherapy. Compliance at 3 and 6 months follow-up was 96-100{\%} for patient-rated, and 8194{\%} for physician-rated assessments. For data collection, 0.4 FTE were allocated in a 183 FTE department (0.2{\%}).Conclusions: ProPED-LUNG is feasible with high compliance rates and yields a large amount of high quality prospective disease-related, treatment-related, patient- and physician-rated data which can be used to evaluate new developments in pulmonary radiotherapy. (C) 2015 Elsevier Ireland Ltd. All rights reserved.",
keywords = "Lung cancer, Thoracic radiotherapy, Patient-rated outcome measures, CELL LUNG-CANCER, PROPHYLACTIC CRANIAL IRRADIATION, THORACIC RADIOTHERAPY, COMPLETE REMISSION, SELECTION",
author = "Niezink, {Anne G. H.} and Dollekamp, {Nienke J.} and Elzinga, {Harriet J.} and Denise Borger and Boer, {Eduard J. H.} and Ubbels, {Jan F.} and {Woltman- van Iersel}, Marleen and {van der Leest}, {Annija H. D.} and Max Beijert and Groen, {Harry J. M.} and Jan Kraan and Hiltermann, {Thijo J. N.} and {Wekken, van der}, {Anthonie J.} and {van Putten}, {John W. G.} and Rutgers, {Steven R.} and Pieterman, {Remge M.} and {de Hosson}, {Sander M.} and Roenhorst, {Anke W. J.} and Langendijk, {Johannes A.} and Joachim Widder",
year = "2015",
month = "4",
doi = "10.1016/j.radonc.2015.03.020",
language = "English",
volume = "115",
pages = "3--8",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "ELSEVIER IRELAND LTD",
number = "1",

}

RIS

TY - JOUR

T1 - An instrument dedicated for modelling of pulmonary radiotherapy

AU - Niezink, Anne G. H.

AU - Dollekamp, Nienke J.

AU - Elzinga, Harriet J.

AU - Borger, Denise

AU - Boer, Eduard J. H.

AU - Ubbels, Jan F.

AU - Woltman- van Iersel, Marleen

AU - van der Leest, Annija H. D.

AU - Beijert, Max

AU - Groen, Harry J. M.

AU - Kraan, Jan

AU - Hiltermann, Thijo J. N.

AU - Wekken, van der, Anthonie J.

AU - van Putten, John W. G.

AU - Rutgers, Steven R.

AU - Pieterman, Remge M.

AU - de Hosson, Sander M.

AU - Roenhorst, Anke W. J.

AU - Langendijk, Johannes A.

AU - Widder, Joachim

PY - 2015/4

Y1 - 2015/4

N2 - Background and purpose: Radiotherapy plays a pivotal role in lung cancer treatment. Selection of patients for new (radio)therapeutic options aiming at improving outcomes requires reliable and validated prediction models. We present the implementation of a prospective platform for evaluation and development of lung radiotherapy (proPED-LUNG) as an instrument enabling multidimensional predictive modelling.Materials and methods: ProPED-LUNG was designed to comprise relevant baseline and follow up data of patients receiving pulmonary radiotherapy with curative intent. Patient characteristics, diagnostic and staging information, treatment parameters including full dose-volume-histograms, tumour control, survival, and toxicity are scored. Besides physician-rated data, a range of patient-rated data regarding symptoms and health-related quality-of-life are collected.Results: After 18 months of accrual, 315 patients have been included (accrual rate, 18 per month). Of the first hundred patients included, 70 received conformal (chemo)radiotherapy and 30 underwent stereotactic radiotherapy. Compliance at 3 and 6 months follow-up was 96-100% for patient-rated, and 8194% for physician-rated assessments. For data collection, 0.4 FTE were allocated in a 183 FTE department (0.2%).Conclusions: ProPED-LUNG is feasible with high compliance rates and yields a large amount of high quality prospective disease-related, treatment-related, patient- and physician-rated data which can be used to evaluate new developments in pulmonary radiotherapy. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

AB - Background and purpose: Radiotherapy plays a pivotal role in lung cancer treatment. Selection of patients for new (radio)therapeutic options aiming at improving outcomes requires reliable and validated prediction models. We present the implementation of a prospective platform for evaluation and development of lung radiotherapy (proPED-LUNG) as an instrument enabling multidimensional predictive modelling.Materials and methods: ProPED-LUNG was designed to comprise relevant baseline and follow up data of patients receiving pulmonary radiotherapy with curative intent. Patient characteristics, diagnostic and staging information, treatment parameters including full dose-volume-histograms, tumour control, survival, and toxicity are scored. Besides physician-rated data, a range of patient-rated data regarding symptoms and health-related quality-of-life are collected.Results: After 18 months of accrual, 315 patients have been included (accrual rate, 18 per month). Of the first hundred patients included, 70 received conformal (chemo)radiotherapy and 30 underwent stereotactic radiotherapy. Compliance at 3 and 6 months follow-up was 96-100% for patient-rated, and 8194% for physician-rated assessments. For data collection, 0.4 FTE were allocated in a 183 FTE department (0.2%).Conclusions: ProPED-LUNG is feasible with high compliance rates and yields a large amount of high quality prospective disease-related, treatment-related, patient- and physician-rated data which can be used to evaluate new developments in pulmonary radiotherapy. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

KW - Lung cancer

KW - Thoracic radiotherapy

KW - Patient-rated outcome measures

KW - CELL LUNG-CANCER

KW - PROPHYLACTIC CRANIAL IRRADIATION

KW - THORACIC RADIOTHERAPY

KW - COMPLETE REMISSION

KW - SELECTION

U2 - 10.1016/j.radonc.2015.03.020

DO - 10.1016/j.radonc.2015.03.020

M3 - Article

VL - 115

SP - 3

EP - 8

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 1

ER -

ID: 21831785